American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Sickle Cell Disease Resources

Resources developed for those working to advance outcomes for persons with sickle cell disease

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Professional Development

Services to support hematologists with continuing medical education and recertification

Practice Resources

Resources to help hematologists understand federal programs, policy developments, and relevant issues affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
  • FDA approves new ofatumumab indication

    On January 19, 2016, the U.S. Food and Drug Administration approved ofatumumab (Arzerra Injection, Novartis Pharmaceuticals Corporation) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab was previously approved for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy was considered inappropriate and also for patients with CLL refractory to fludarabine and alemtuzumab.

  • FDA Approves Ixazomib in Combination with Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

    On November 20, 2015, the U.S. Food and Drug Administration approved ixazomib (NINLARO, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor.

  • FDA Grants Accelerated Approval to Daratumumab for Multiple Myeloma

    On November 16, 2015, the U.S. Food and Drug Administration granted accelerated approval to daratumumab injection (DARZALEX™, Janssen Biotech, Inc.), administered as a single agent for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.

  • FDA Grants Accelerated Approval to Idarucizumab for the Reversal of Anticoagulant Effects of Dabigatran

    On October 16, 2015, the U. S. Food and Drug Administration granted accelerated approval to idarucizumab (Praxbind Injection, Boehringer Ingelheim Pharmaceuticals, Inc.) for the treatment of patients treated with dabigatran (Pradaxa) when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures, or in life-threatening or uncontrolled bleeding.

View all FDA alerts
  • New CMS Data Release Shows the Growth in Costs from Drugs Associated with Hematologic Conditions

    The Center for Medicare and Medicaid Services (CMS) released new data in December on prescription drugs. The data shows the large and increasing costs associated with prescription drugs, including a number which are associated with the care for hematologic conditions. The high costs of drugs is even more apparent when compared to other costs within the health care system. The cost of the single most expensive hematologic drug is almost equal to the spending for all specialists in hematology and oncology.

  • Is the Network Too Narrow for Hematology?

    Changes from the ACA are putting pressure on insurers. In response, some insurers could start building networks that exclude important hematology services.

  • Medicare Finalizes Payment Rates for Inpatient Hospital Services in Fiscal Year 2015

    The Centers for Medicare and Medicaid (CMS) released the inpatient hospital final rule for fiscal year 2015, detailing payment rates and other related policy for the fiscal year that starts on October 1, 2014.  ASH commented on a number of items in the proposed rule.

View all policy news
back to top